IOPIDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Iopidine, and what generic alternatives are available?
Iopidine is a drug marketed by Harrow Eye and is included in two NDAs.
The generic ingredient in IOPIDINE is apraclonidine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apraclonidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iopidine
A generic version of IOPIDINE was approved as apraclonidine hydrochloride by RISING on March 12th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IOPIDINE?
- What are the global sales for IOPIDINE?
- What is Average Wholesale Price for IOPIDINE?
Summary for IOPIDINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Clinical Trials: | 1 |
| Patent Applications: | 381 |
| Drug Prices: | Drug price information for IOPIDINE |
| What excipients (inactive ingredients) are in IOPIDINE? | IOPIDINE excipients list |
| DailyMed Link: | IOPIDINE at DailyMed |
Recent Clinical Trials for IOPIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alabama at Birmingham | Phase 4 |
Pharmacology for IOPIDINE
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
US Patents and Regulatory Information for IOPIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020258-001 | Jul 30, 1993 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IOPIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020258-001 | Jul 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for IOPIDINE
See the table below for patents covering IOPIDINE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1194418 | COMPOSITIONS A BASE DE 2-(PHENYLIMINO TRISUBSTITUE)- IMIDAZOLINE POUR L'ABAISSEMENT DE LA PRESSION INTRAOCULAIRE (2-(TRISUBSTITUTED PHENYLIMINO)-IMIDAZOLINE COMPOSITIONS FOR LOWERING INTRAOCULAR PRESSURE) | ⤷ Sign Up |
| Japan | H0453846 | ⤷ Sign Up | |
| European Patent Office | 0081924 | TOPICAL COMPOSTIONS FOR LOWERING INTRAOCULAR PRESSURE | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IOPIDINE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0081924 | SPC/GB93/103 | United Kingdom | ⤷ Sign Up | SPC/GB93/103:, EXPIRES: 20071118 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
